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Summary Myeloproliferative neoplasms (MPN) are clonal
haemopoietic progenitor cell disorders characterized by the
proliferation of one or more of the haemopoietic lineages
(myeloid, erythroid and/or megakaryocytic). The MPNs
include eight haematological disorders: chronic myeloge-
nous leukemia (CML), polycythemia vera (PV), essential
thrombocythemia (ET), primary myelofibrosis (PMF),
systemic mastocytosis (SM), chronic eosinophilic leukemia,
not otherwise specified (CEL, NOS), chronic neutrophilic
leukemia (CNL), and unclassifiable MPN (MPN, U).
Therapeutic interventions for MPNs include the use of
tyrosine kinase inhibitors (TKIs) for BCR-ABL1
+ CML
and JAK2 inhibitors for PV, ET and PMF. Histone
deacetylase inhibitors (HDACi) are a novel class of drugs
capable of altering the acetylation status of both histone and
non-histone proteins, thereby affecting a repertoire of
cellular functions in neoplastic cells including proliferation,
differentiation, immune responses, angiogenesis and sur-
vival. Preliminary studies indicate that HDACi when used in
combination with tyrosine kinase or JAK2 inhibitors may
overcome resistance to the latter agents and enhance the pro-
apoptotic effects on MPN cells. This review provides a
review of pre-clinical and clinical studies that have explored
the use of HDACi as potential therapeutics for MPNs.
Keywords Myeloproliferative neoplasms.Deactylase
inhibition.Epigenetic therapy.Chronic myelogenous
leukemia
Introduction
Myeloproliferative neoplasms
The World Health Organization (WHO) classification of
haemopoietic and lymphoid neoplasms was revised in 2008
[1]. This represented a major improvement over the 2001
WHO classification system, whereby myeloid neoplasms
are now classified into five categories: acute myeloid
leukemia (AML), myelodysplastic syndromes (MDS),
myeloproliferative neoplasms (MPN), MDS/MPN, and
myeloid and/or lymphoid malignancies associated with
eosinophilia and platelet-derived growth factor receptor
(PDGFR) or fibroblast growth factor receptor 1 (FGFR1)
rearrangements. MPN are sub-classified into eight separate
entities: chronic myelogenous leukemia (CML), polycythe-
mia vera (PV), essential thrombocythemia (ET), primary
myelofibrosis (PMF), systemic mastocytosis (SM), chronic
eosinophilic leukemia, not otherwise specified (CEL,
NOS), chronic neutrophilic leukemia (CNL), and unclassi-
fiable MPN (MPN,U).
The MPN are clonal haemopoietic stem cell disorders
characterized by proliferation of one or more haemopoietic
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DOI 10.1007/s10637-010-9590-4lineages. Occurrence is primarily in the 5th to 7th decade of
life, however, CML and ET have been described in
children. The incidence of MPN as a group is 6-10/
100,000 population annually [2]. Collectively, MPN are
characterised by a hypercellular bone marrow with effective
haemopoiesis. Over time splenomegaly and hepatomegaly
occur as a result of sequestration of blood cells and extra-
medullary proliferation of haemopoietic cells. Despite an
initially indolent course MPN progress over time and have
the potential to transform to acute leukaemia. This
manifests clinically as progressive organomegaly, worsen-
ing of peripheral cytopenias and an increasing numbers of
circulating blast cells.
The diagnosis of CML requires the presence of BCR-
ABL1, while its absence is required for all other MPN.
CML remains the prototype for the identification and
classification of myeloid neoplasms. The enhanced tyrosine
kinase activity of BCR-ABL1 results in constitutive
activation of a number of signal transduction pathways
resulting in the leukemic phenotype observed in CML.
BCR-ABL1 provided the first bona fide therapeutic target
for tyrosine kinase inhibitors (TKIs). This has revolution-
ized the management of CML, a disorder previously fatal
without allogeneic stem cell transplantation.
PV, ET, and PMF make up the non-leukemic MPN.
Clonal proliferation is responsible for the overlapping
expansion of erythropoietic, granulopoietic, and megakar-
yocytic components in the marrow and, in advanced
disease, the liver and spleen. A single acquired point
mutation (V617F) of the cytoplasmic Janus-associated
tyrosine kinase (JAK2) occurs (heterozygous or homozy-
gous) in the marrow and blood of almost all patients with
PVand in approximately 50% of patients with ETand PMF,
and is responsible for the uncontrolled myeloproliferation
associated with these disorders. JAK2 is involved in
transducing signals from cytokines and growth factors
including erythropoietin (EPO), granulocyte-macrophage
colony-stimulating factor (GM-CSF) and thrombopoietin
(TPO). The mutation occurs in a highly conserved region of
the pseudokinase domain that is believed to negatively
regulate JAK2 signaling. In PV, the presence of JAK2
homozygosity increases with time. Additional MPN-
associated molecular markers include mutations of MPL,
TET2 and KIT but the diagnostic utility of MPL and TET2
mutations is limited by a low mutational frequency.
In SM, presence of the D816V KIT mutation is expected
but not essential for diagnosis. CEL, NOS should be
distinguished from both PDGFR-rearranged or FGFR1-
rearranged neoplasms and hypereosinophilic syndrome
(HES). CNL is a rare myeloproliferative disease with only
150 cases reported [1] and is characterized by sustained
neutrophilia, bone marrow hypercellularity and hepatosple-
nomegaly. The BCR-ABL1 fusion gene is undetectable in
CNL and further discrimination is required to distinguish
CNL from other MPNs.
Prognosis
Prior to any effective therapy the median survival for CML
was 2–3 years [3]. Subsequently, intereferon-γ (IFN-γ)-
based approaches resulted in 10 year overall survival (OS)
rates of approximately 25% [4]. The 10-year OS for
allogeneic haemopoietic stem cell transplantation (HSCT)
varied widely from 10 to 70% depending on patient age,
phase of disease and donor type [5, 6]. In the current era of
tyrosine kinase inhibitor (TKI) therapy 5-year OS with
imatinib is 80–95% [5, 7], however, acquired resistance to
imatinib in patients leads to a clinical impasse. In addition to
BCR-ABL1 gene amplification resulting in overexpression of
BCR-ABL1 protein, or point mutations that prevent the
binding of the inhibitor to the kinase domain [8, 9], several
groups have demonstrated other forms of BCR-ABL1-
independent imatinib resistance [10–12]. Interestingly,
BCR-ABL1-independent imatinib-resistant K652 cells dis-
play aberrant protein acetylation and increased sensitivity to
histone deactylase inhibitors (HDACi) [12].
PV and ET are relatively indolent disorders that result
in a modest reduction of survival, particularly evident
after the first decade from diagnosis. In contrast, PMF
has a more aggressive clinical course with a median
survival of approximately 5 years, although younger
patients with low-risk disease may experience survival in
excess of 10 years [13]. With the possible exception of
IFN-γ use in PV [14–16], therapy for classical MPN is
aimed at ameliorating the signs and symptoms of myelo-
proliferation, including anaemia and/or thrombocytopenia,
and to reduce the risk of thrombosis. Patients with PMF
and post-ET/PV MF have progressive cytopenias, extra-
medullary haemopoiesis (manifesting as splenomegaly
and/or hepatomegaly), significant constitutional symp-
toms, the potential for blastic transformation and subse-
quently, premature death [17, 18]. A number of novel
therapeutic strategies have been explored in these patients
including farnesyl-transferase inhibition [19], proteosome
inhibition [20] and immunomodulation with lenalidomide
[21] but with limited efficacy. Since current therapies
rarely offer more than a palliative benefit, the urgent need
for improved therapeutic options for PMF and post-ET/PV
MF has resulted in therapeutic targeting of the
JAK2V617F mutation, a common molecular link that
unifies the pathogenesis of these MPNs. A selective JAK1/
2 inhibitor, INCB018424, demonstrated prolonged surviv-
al in a preclinical murine model of JAKV617F+MPN [22]
and preliminary results from a phase 1/2 study resulted in
objective and subjective improvements in patients with
PMF and post-ET/PV MF [22]. These targeted therapeutic
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need to be explored.
Epigenetic therapy in MPN
Despite the general acceptance that genetic changes
underlie the pathogenesis of cancer there is an increasing
body of evidence demonstrating that in malignant cells
epigenetic changes result in the abnormal transcription of
structurally intact genes. In general, malignant tissue is
characterized by global hypermethylation of DNA [23, 24].
In addition, malignant tissues also demonstrate increased
histone deacetylation that results in chromatin condensation
and transcriptional repression of tumor suppressor genes
[24–26]. Collectively, these post-translational modifications
of histones and DNA methylation result in transcriptional
silencing of tumour suppressor and cell differentiation
genes, thus promoting cell survival by blocking apoptosis
and senescence. Importantly, epigenetic but not genomic
changes have the potential to be modulated for therapeutic
benefit. Novel therapeutic approaches are now being
developed to target some of these molecular lesions,
including epigenetic alterations, by making use of methyl-
transferase and histone deacetylase inhibitors. However, the
extent and specific role of epigenetic modifications in MPN
remain poorly understood. Furthermore, increased knowl-
edge of the linkage between genetic and epigenetic changes
that promote tumourogenesis and the identification of
appropriate biomarkers represents a prerequisite for suc-
cessful epigenetics-directed MPN therapy. The production
of pro-inflammatory cytokines by stromal elements and
constitutive activation of aberrant signal transduction path-
ways by malignant cells could result in disease progression.
Indeed, the constitutive activation of the JAK/STAT
pathway in JAKV617F+MPN can result in subsequent
epigenetic silencing of tumour suppressor genes [27, 28],
suggesting that these changes result in further evolution of
the disease.
Epigenetic events in MPN are most prevalent in PMF as
evidenced by genome-wide methylation studies demon-
strating a high rate of methylation in samples from PMF
patients [29, 30]. In addition, a decreased level of
acetylation as a result of increased histone deacetylase
activity has also been observed [30]. Most of the work on
gene methylation in MPN has focused on a limited number
of genes, in particular, the status of the suppressors of
cytokine signaling family proteins (SOCS) [31–34]. The
increased number of CD34-positive cells in the peripheral
blood of PMF patients has been attributed to the reduced
membrane expression of C-X-C chemokine receptor type 4
(CXCR4) [35, 36] which is secondary to increased
methylation of the CpG islands of the CXCR4 promoter
[37]. Ex vivo treatment of CD34-positive cells from PMF
patients with hypomethylating agents rectified the abnormal
homing and proliferation of these cells [38]. Wang et al.,
(2008) demonstrated increased HDAC levels in the CD34-
positive cell fractions of patients with PMF [30]. Given
these changes, it would seem reasonable to explore
epigenetic therapy as a therapeutic option in MPN,
especially PMF, where therapeutic options are currently
limited. The use of DNA hypomethylation therapy has been
found to be efficacious in patients with MDS leading to
improvement in disease-associated cytopenias, delay in
transformation to AML and improved OS [39, 40],
however, the hypomethylating agent 5-azacytidine has
limited efficacy in PMF [17, 41].
Histone deacetylases and inhibitors
Acetylation of proteins is modulated by the dynamic and
antagonistic action of two classes of enzymes, histone
deacetylases (HDACs) and histone acetyltransferases
(HATs). HATs acetylate amino –terminal lysine residues
whereas HDACs catalyse the removal of acetyl groups. The
HDAC family comprises 18 genes, grouped into 4 classes
based on their homology to yeast orthologues. Class I
(HDACs 1–3 and 8), Class II A (HDAC 4,5,7 and 9), Class
II B (HDAC6 and 11) and Class IV (HDAC11) require zinc
for catalysing deactylase activity, while Class III (Sirutins
1–7) utilise nicotine adenine dinucleotide (NAD
+) for their
catalytic mechanisms [26, 42]. Moreover, there is growing
evidence that the acetylation status of proteins plays a key
role in the regulation of cellular signalling and disease
development [27, 42–48].
HDACi represent a novel class of chemotherapeutic
drugs that are able to regulate cellular functions through
their ability to inhibit HDAC action and can be subdivided
into six groups based on their structure: Hydroxamic acid-
derived compounds, cyclic peptides, short-chain fatty acids,
benzamides, electrophilic ketones and several agents that
are not otherwise classifiable [49]. Their inhibitory effects
on cell proliferation and survival can be mediated by both
chromatin-dependent (acetylation of histone proteins) and
chromatin-independent pathways (acetylation of non-
histone proteins). Alterations in gene expression induced
by histone acetylation results in changes in expression
levels of pro- and anti-apoptotic genes and modulation of
cell cycle genes (reviewed in [48, 50]). Amongst the non-
histone acetylation targets that via HDACi induced acety-
lation could potentially impart anti-cancer effect are
transcription factors (p53, c-Myc, Smad7, BCL6, GATA,
STAT3, NF-κB, E2F family, MEF2, AML1, CREB), chaper-
one proteins (Hsp90), cytoskeletal proteins (α-tubulin),
nuclear import proteins (Importin α), DNA repair enzymes
(Ku70) and steroid receptors (androgen receptors, estrogen
receptor)(reviewedin[46, 51, 52]). Furthermore, HDACi are
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formed cells to induce growth arrest and apoptosis, although
the molecular mechanisms underlying the apparent specific-
ity of HDACi to induce cytotoxicity of neoplastic cells and
not normal cells remains to be elucidated [53–57].
MPN and HDAC inhibitors
BCR-ABL1+ chronic myelogenous leukemia
Chronic Myeloid Leukemia (CML) is a MPN of myeloid
progenitor cells characterised by the expression of a 210-
KDa fusion oncoprotein, BCR-ABL, resulting from the
juxtapositioning of chromosomes 9 and 22 [the Philadel-
phia chromosome translocation, t(9;22)]. The BCR-ABL
kinase is constitutively active and via downstream signaling
regulates multiple survival pathways, including Ras/Raf/
mitogen-activated protein kinase (MEK)/extracellular
signal-regulated kinase (ERK), PI3/AKT, NF-κB, JAK/
STAT, anti- and pro-apoptotic proteins [58]. Monotherapy
with the TKI imatinib mesylate is effective in chronic-phase
CML patients, however, accelerated and blast phase
patients are generally resistant to imatinib [59]. Imatinib
resistance is usually characterized by amplification of the
BCR-ABL gene, protein overexpression, missense muta-
tions in BCR-ABL kinase domains or through mechanisms
independent of BCR-ABL signalling [10–12, 60, 61].
Dasatinib and nilotinib are two novel second generation
kinase inhibitors that are effective in imatinib-resistance
patients, although patients with the T315I BCR-ABL
mutation do not respond to these drugs [62, 63]. Therefore,
additional therapies to combat emergent TKI resistance are
required and are currently being explored.
Recent studies indicate that HDACi are capable of
attenuating the expression of BCR-ABL and of inducing
apoptosis in both imatinib sensitive and resistant cell lines
[64–69]. Furthermore, the tumour-specificity of HDACi
was seen with HDACi preferentially affecting the BCR-
ABL positive clonal cells and not normal cells [70–73]. In
addition, analyses of the expression and functional activity
of HDACs and HATs in the imatinib resistant CML cell line
K562 have indicated that Class I (HDAC1, 2 and 3), Class
IIA (HDAC4) and Class III (SIRT1) HDACs are all
elevated and increased compared to imatinib sensitive cells,
whereas the levels of HATs are decreased [12, 74]. To date,
several HDACi that have been tested against CML cells
include suberoylanilide hydroxamic acid (SAHA [Vorino-
stat]), LBH589 (Panobinostat), LBQ824, apicidin, FK-228
(Romidepsin [Depsipeptide]), valproate, sodium butryate
and AN-9 (Pivanex). In most of the studies performed the
primary mechanism by which HDACi appeared to induce
apoptosis in CML cells was through the reduction of BCR-
ABL levels and therefore downregulation of the multiple
signalling pathways controlling survival of the neoplastic
cells. As such, while the expression of HDACs and HATs
in imatinib-responsive and refractory patient samples has
not been assessed it would appear that HDAC inhibition
may represent a promising anti-leukemic approach for
imatinib-refractory patients.
The pan-HDAC inhibitors SAHA, LBH589 and
LAQ824 display inhibitory activity against both Class I
and Class II HDACs and are therefore able to modulate a
diverse range of proteins involved in growth arrest and
apoptosis [26, 49, 57, 75]. SAHA, one of the most
investigated compounds, has been used in preclinical
studies of human imatinib-sensitive and –resistant cell lines
and in CD34+ cells from imatinib-refractory patients either
alone or in combination with kinase inhibitors [12, 68, 70,
76, 77], proteosome inhibitors [78]o raM E K / E R K
pathway inhibitor [73]. LBH589 and LAQ824 also induce
cytotoxicity in imatinib-refractory CML cell lines and/or
patient samples both alone and in combination with other
agents [64, 65, 67]. Apicidin overcomes resistance to TNF-
related apoptosis inducing ligand (TRAIL) in K562 cells
via inhibition of the PI3K/AKT pathway and nuclear
translocation of NF-κB with a subsequent reduction in
Bcl-xL expression [79]. Likewise, FK228 induces cell cycle
arrest and apoptosis of imatinib-resistant CML cells and in
primary patient samples, in contrast however, expression of
Bcl-xL, Bcl-2 or Bax does not change [80, 81]. In addition,
Okabe et al., demonstrated that FK228 treatment induces a
diverse range of histone and non-histone protein acetylation
in BCR-ABL transfected cell lines, including acetylation of
p53, Hsp90 and BCR-ABL [81]. Valproate, commonly
used as an anti-epileptic drug, enhances imatinib-induced
growth arrest and apoptosis in CML cell lines and primary
mononuclear cells with concomitant p21
CIP1 upregulation,
Bcl-2 downregulation and interference with NF-κB DNA
binding [66, 82]. Sodium butyrate (SB) or AN-9 (Pivanex)
alone or in combination with the MEK inhibitor PD184352,
bortezomib or imatinib results in synergistic lethality of
CML cell lines [73, 78, 83, 84]. Importantly, combination
treatments of TKI-resistant neoplastic cells appear to
overcome drug resistance compared to treatment with
HDACi alone [64–66, 68, 70, 72, 73, 76–80, 84].
Overcoming drug resistance could be attributed to either
the synergistic reduction of BCR-ABL protein levels and/or
conceivably the elimination of leukemia stem cells by
HDACi that are not affected by conventional TKI treatment
[85].
In general, HDACi induce apoptosis in neoplastic cells
by modulating multiple signalling pathways that orchestrate
proliferation, differentiation and survival. Their anti-
proliferative effect is mediated through increased produc-
tion of cell cycle inhibitor proteins p21
CIP1 [64–68, 72, 73,
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KIP1 [64, 67, 68],
attenuation of cyclin D1 [73, 78] and hypophosphorylation
of the retinoblastoma (Rb) protein [45]. While HDACi
treatment alone induces chromatin-dependent transactiva-
tion of p21
CIP1 expression resulting in growth arrest,
combination treatment with a MEK1/2 inhibitor or the
multikinase inhibitor Sorafenib abrogates p21
CIP1 induction
resulting in enhanced apoptosis [73, 77]. Indeed, p21
CIP1 is
known to oppose apoptosis through multiple mechanisms,
including inhibition of caspase-3 activation [86, 87].
Therefore, whereas HDACi mediated p21
CIP1 expression
induces cell cycle arrest, cell lethality may require p21
CIP1
downregulation. The expression of p27
KIP1 appears to be
related to a non-transcriptional mechanism and possibly a
consequence of BCR-ABL mediated regulation through the
PI3K/AKT pathway [67, 88]. Lethality results from
activation of both the extrinsic and intrinsic apoptotic
pathways [37, 40, 43, 44], through production of reactive
oxygen species (ROS) [71, 73, 78] and by the induction of
autophagy [71]. In particular, induction of pro-apoptotic
Bim and in some instances, a decrease in pro-survival Bcl-
xL is critical for HDACi mediated apoptosis [64, 67, 69, 76,
79]. Finally, the proteosome inhibitor bortezomib or the
MEK pathway inhibitor PD184352 when used in combi-
nation with SAHA also affects multiple signalling path-
ways, including induction of Jun Kinase (JNK)
phosphorylation, inactivation of AKT and abrogation of
NF-κB DNA binding [73, 78, 79].
Treatment with HDACi also influences gene expression
through chromatin-independent mechanisms by acetylating
non-histone proteins. However, studies that specifically focus
onchromatin-independent targetsofHDACi inCML cells are
limited. Some of the non-histone HDAC substrates that are
known to be involved in the cytotoxicity of CML cells post
HDACi exposure are Hsp90, p53, Ku70 and α-tubulin.
Importantly, imatinib-resistant K562 cells display hypoacety-
lation of these non-histone proteins [12, 73]. Acetylation of
Hsp90, a HDAC6 substrate, results in accelerated degreda-
tion of HSP90 client proteins, including BCR-ABL, AKT
and c-Raf, via the 26S proteosome [65, 76, 89–91].
Reduction of BCR-ABL levels post-HDACi treatment,
observed in most cases of HDACi treated CML cells,
appears to be a consequence of disrupted Hsp90 chaperone
function and proteosomal degradation of BCR-ABL [12, 65,
67, 76]. Ku70, a DNA repair enzyme, is another known
HDAC substrate and when deacetylated it sequesters the
proapoptotic protein Bax in the cytoplasm rendering it
inactive. Acetylation of Ku70 by HATs is integral to stress-
induced lethality by Bax [92]. In imatinib-resistant K562 cell
line, the expression of cytoplasmic Ku70 is increased, while
the amount of acetylated Ku70 is markedly decreased,
suggesting that Bax-mediated apopotosis is inhibited [12].
Transcriptional activation of the tumour suppressor p53 by
acetylation also plays a key role in HDACi mediated cell
cycle arrest and apoptosis. Deacetylation of p53 by HDAC1–
3 or SIRT1 inhibits its transcriptional activity, and subse-
quently, the activation of its downstream molecules, Bax and
p21 [93–95]. Therefore, acetylation of intracellular proteins
by HDACi likely plays a critical role in orchestrating the
cellular fate of leukemic cells.
‘Classic’ MPN
The safety and efficacy of HDACi in the treatment of patients
withMPNhasbeenevaluatedina smallnumberofpreclinical
and phase I/II studies. The rationale for the use of HDACi in
MPN stems from pre-clinical studies that have demonstrated
enhanced sensitivity of JAK2V617F mutated versus non-
mutated cells derived from patients with PVor PMF [96, 97].
Epigenetic therapy provides a promising platform for the
treatment of PMF; evidence for this was provided by the
preferential reduction in the number of JAK2V617F-positive
progenitor cells when sequential administration of 5-aza-2′-
deoxycytidine (a DNA methyltransferase inhibitor) and
Trichostin A (a pan-HDAC inhibitor) was performed [97].
Furthermore, quantitative analysis of Class I-III HDACs
mRNA expression and activity in CD34+ cells from PMF
patients reveals that HDAC1, 2, 6, 8, 10 and SIRT1, 2, 3, 5
and 7 are overexpressed, while HDAC4, 5 and 11 and SIRT4
are downregulated [30]. The pattern of HDAC mRNA
expression did not correlate with the JAK2V617F
mutation status, furthermore, the relevance of the
aberrant PMF CD34+ cell HDAC mRNA expression
and activity and subsequent effects on biological function
and pathogenesis of PMF are unknown.
Exposure of mutant cells to the Class I and II HDAC
inhibitor, ITF2357, down-regulated JAK2V617F, p-STAT3
and p-STAT5 levels [96]. An ITF2357 Phase IIA study
demonstrated efficacy in PV, ETand PMF patients with rapid
improvement of constitutional symptoms, reduction in
splenomegaly and improved haemopoietic function [97].
Treatment of CD34+ PMF-MPN cells with LBH589 induces
apoptosis of PMF-MPN cells and inhibits the expression and
activity of JAK2V617F with a subsequent reduction in p-
STAT3, p-STAT5, p-AKT, p-GATA-1 and Bcl-xL [98]. In
addition, the binding of HSP90 to JAK2 was partially
inhibited by LBH589 treatment suggesting that acetylation of
HSP90 could be playing a role in the degradation of JAK2
protein. Synergistic induction of MPN cell apoptosis was
also observed when LBH589 and a JAK2 inhibitor
(TG101209) were combined [98]. A Phase IA/II trial
evaluating oral LBH589 in patients with PMF (n=10) and
post-PV MF (n=3) that included 9 patients with
JAK2V617F mutation exhibited clinical activity for up to
39 months including a reduction in spleen size and
improvement in constitutional symptoms [99]. Similarly,
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PMF or post-ET/PV MF demonstrated clinical efficacy in
6 patients (regardless of JAK2V617F mutation status) with
minimal toxicity [100]. In addition, a single case report
has described an improvement in cytopenias in a patient
with post-ET MF with the use of vorinostat [101].
Conclusion
Therapeutic interventions for MPNs include the use of highly
targeted and efficacious therapy with TKIs for the abnormal
BCR-ABL fusion protein found in CML and the use of less
specific agents, including JAK2 inhibitors, that target ubiqui-
tously expressed proteins in JAKV617F mutated PV, ET and
PMF. Despite TKIs revolutionising the management of CML,
TKI resistance can occur through BCR-ABL-independent
mechanisms that may at least in part be due to abnormal
acetylation of non-histone proteins. Furthermore, abnormal
histone deacetylase activity has been noted in PMF and
provides a rationale for the treatment of MPN with HDACi,
either alone or in combination with existing therapies.
Preliminary studies indicate that HDACi when used in
combination with TKIs or JAK2 inhibitors may overcome
drug resistance and enhance the apoptotic effects on MPN
cells. HDACi likely induce lethality through a combination of
both epigenetic (chromatin-dependent) and non-epigenetic
(chromatin-independent) changes. Importantly, epigenetic but
not genomic changes have the potential to be modulated for
therapeutic benefit, however, the extent and specific role of
epigenetic aberrations such as histone deacetylase activity in
MPN are still poorly understood. Increased knowledge of the
linkage of genetic and epigenetic changes that promote
tumorogenesis represents a prerequisite for successful
epigenetic-directed MPN therapy. Further pre-clinical and
phase I/II studies are required to ascertain the utility of
HDACiinthemanagementofselectedindividualswithMPN.
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